First, they provided radiation. Then, they added chemotherapy and laboratory services, surgery and rehabilitation therapy. Now, MD Anderson’s regional care centers are allowing patients to enroll in clinical trials that offer hope and could change how certain diseases are treated in the future.
In 2011, James Yao, M.D.,and his colleagues published pivotal findings from a Phase III randomized trial showing that everolimus dramatically improved progression-free survival for patients with advanced pNET (pancreatic neuroendocrine tumors). Before that, there were no large-scale, well-conducted randomized studies to guide treatment decisions and only one approved therapy for the treatment of this disease.